LPCN logo

LPCN
Lipocine Inc

14,537
Mkt Cap
$18.55M
Volume
82,749.00
52W High
$12.37
52W Low
$1.81
PE Ratio
-1.15
LPCN Fundamentals
Price
$2.25
Prev Close
$2.26
Open
$2.24
50D MA
$3.36
Beta
0.70
Avg. Volume
980,800.20
EPS (Annual)
-$1.77
P/B
0.74
Rev/Employee
$141,191.21
$28.82
Loading...
Loading...
News
all
press releases
Lipocine Announces LPCN 1154 Phase 3 Data Accepted for Oral Presentation at 2026 ASCP Annual Meeting
Lipocine Announces LPCN 1154 Phase 3 Data Accepted for Oral Presentation at 2026 ASCP Annual Meeting Lipocine Announces LPCN 1154 Phase 3 Data Accepted for Oral Presentation at 2026 ASCP Annual...
PR Newswire
News Placeholder
More News
News Placeholder
Lipocine to Present at A.G.P.'s Annual Virtual Healthcare Company Showcase
Lipocine to Present at A.G.P.'s Annual Virtual Healthcare Company Showcase Lipocine to Present at A.G.P.'s Annual Virtual Healthcare Company Showcase PR Newswire SALT LAKE CITY, May 18, 2026 SALT...
PR Newswire
News Placeholder
Lipocine Announces Financial Results for the First Quarter Ended March 31, 2026
Lipocine Announces Financial Results for the First Quarter Ended March 31, 2026 Lipocine Announces Financial Results for the First Quarter Ended March 31, 2026 PR Newswire SALT LAKE CITY, May 7, 2026...
PR Newswire
News Placeholder
Lipocine (LPCN) Reports Q1 Loss, Beats Revenue Estimates
Lipocine (LPCN) delivered earnings and revenue surprises of -5.88% and +19.40%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
News Placeholder
BioCryst Pharmaceuticals (BCRX) Reports Q1 Loss, Beats Revenue Estimates
BioCryst (BCRX) delivered earnings and revenue surprises of -150.00% and +0.06%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
News Placeholder
Lipocine (NASDAQ:LPCN) Director Buys $81,200.00 in Stock
Lipocine Inc. (NASDAQ:LPCN - Get Free Report) Director John Higuchi bought 40,000 shares of the firm's stock in a transaction dated Tuesday, April 7th. The stock was purchased at an average cost of...
MarketBeat
News Placeholder
Mahesh Patel Purchases 25,000 Shares of Lipocine (NASDAQ:LPCN) Stock
Lipocine Inc. (NASDAQ:LPCN - Get Free Report) CEO Mahesh Patel purchased 25,000 shares of Lipocine stock in a transaction that occurred on Monday, April 6th. The shares were bought at an average cost...
MarketBeat
News Placeholder
What's Going On With Lipocine Stock On Monday?
Lipocine stock rebounds after a steep drop as LPCN 1154 misses the Phase 3 endpoint, with encouraging subgroup data.read more...
Benzinga
News Placeholder
Insider Buying: Lipocine (NASDAQ:LPCN) CEO Purchases 25,000 Shares of Stock
Lipocine Inc. (NASDAQ:LPCN - Get Free Report) CEO Mahesh Patel purchased 25,000 shares of the company's stock in a transaction that occurred on Thursday, April 2nd. The shares were acquired at an average cost of $2.02 per share, with a total value of $50,500.00. Following the completion of the...
MarketBeat
News Placeholder
LPCN Stock Crashes 78%— Here’s Why
Lipocine said that its experimental drug LPCN 1154 did not bring about a significant reduction in the severity of postpartum depression in a trial.
Stocktwits
<
1
2
...
>

Compact View

Mini-Chart
Sentiment
Not available
Message Volume
Not available